CD15s expression (LAD 2), as part of a Leukocyte Adhesion Deficiency (CD15s, CD18) panel from Quest Diagnostics, plays a critical role in diagnosing Leukocyte Adhesion Deficiency Type II (LAD II). This condition is a rare genetic disorder that affects the immune system's ability to function properly. In healthy individuals, CD15s (also known as sialyl-Lewis X) is a specialized molecule present on the surface of white blood cells (leukocytes) that facilitates their adhesion, or sticking, to blood vessel walls during inflammation or infection. This process is essential for the immune response, as it allows leukocytes to exit the bloodstream and enter affected tissues to combat pathogens. In LAD II, there is a deficiency or dysfunction in CD15s expression, which impairs this critical adhesion process. As a result, patients with LAD II typically suffer from recurrent bacterial infections, delayed wound healing, and other complications due to their leukocytes' inability to properly adhere and migrate to sites of infection. Diagnosing LAD II involves detecting abnormalities in CD15s expression through panels like the one offered by Quest Diagnostics. Treatment usually focuses on managing infections and may include antibiotics, preventive measures to avoid infections, and in some cases, bone marrow transplantation, which can help correct the underlying defect in leukocyte function.
CD15S EXPRESSION (LAD 2)
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.